Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss SAN DIEGO, June 24, 2026...

Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval SAN DIEGO, June 11, 2026 /PRNewswire/ -- Viking Therapeutics,...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...